Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

There's no question about it, McDonald's is the most successful restaurant in the history of the world. The company isn't ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

The last-twelve month period sales of $9 billion align with the ... we think the potential headwinds for Gardasil are largely priced in. While MRK stock looks like it can see higher levels ...

Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug ... % in the past year compared with a decline of 3.9% for the industry. Merck MRK stock has declined ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE ... MRK’s leading HPV vaccine, GARDASIL 9, faced challenges internationally due to inventory buildup within its ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

Follow along today for ongoing coverage of Robert F. Kennedy Jr.'s second Senate confirmation hearing.  | Coverage of Robert ...